Risk reduction associated with lowering systolic blood pressure: Review of clinical trial data

American Heart Journal

Volumn 138, Issue 3 II, 1999, Pages

  Hall, W D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; CHLORTALIDONE; ENALAPRIL; HYDROCHLOROTHIAZIDE; NITRENDIPINE;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

EID: 0032849122     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-8703(99)70314-5     Document Type: Review

References (21)

1. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements. In: Kannel WB, Wolf PA, Garrison RJ, editors. Framingham Heart Study, 30-year follow-up. Bethesda, Md: National Institutes of Health; 1987, publication NIH 87-2703.
2. Wilson PW, Anderson KM, Castelli WP. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham Offspring Study. Am J Med 1991;90:11-6.
3. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men: Multiple Risk Factor Intervention Trial (MRFIT). Arch Intern Med 1992;152:56-64.
4. Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med 1993;329:1912-7.
5. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
6. Staessen J, Amery A, Fagard R. Isolated systolic hypertension in the elderly. J Hypertens 1990;8:393-405.
7. Pahor M, Guralnik JM, Furberg CD, et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996;347:1061-5.
8. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium- channel blockade and incidence of cancer in aged populations. Lancet 1996;348:493-7.
9. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986;293:1145-51.
10. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-5.
11. Lindholm LH, Hansson L, Dahlöf B, et al. The Swedish Trial in Old Patients with Hypertension-2 (STOP-Hypertension-2): a progress report. Blood Press 1996;5:300-4.
12. Ekbom T, Dahlöf B, Hansson L, et al. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study. J Hypertens 1992;10:1525-30.
13. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.
14. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64.
15. Kostis JB, Berge KG, Davis BR, et al, for the SHEP Cooperative Research Group. Effect of atenolol and reserpine on selected events in the Systolic Hypertension in the Elderly Program (SHEP). Am J Hypertens 1995;8:1147-53.
16. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose- related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
17. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
18. Kaplan NM. Systolic Hypertension in the Elderly Program (SHEP) and Swedish Trial in Old Patients with Hypertension (STOP): the promises and the potential problems. Am J Hypertens 1992;5:331-4.
19. Ménard J, Day M, Chatellier G, et al. Some lessons from Systolic Hypertension in the Elderly Program (SHEP). Am J Hypertens 1992;5:325-30.
20. Staessen J, Fagard R, Amery A. Isolated systolic hypertension in the elderly: implications of SHEP for clinical practice and for the ongoing trials. J Hum Hypertens 1991;5:469-74.
21. Staessen JA, Amery A, Birkenhäger W. Inverse association between baseline pressure and benefit from treatment in isolated systolic hypertension. Hypertension 1994;23:269-70.